Coagulation Products

Home/Coagulation Products

Antibodies and Proteins

An important tool in studying protein function in cells, our antibodies and proteins are ideal for research and in the study of bleeding & clotting diseases.

Anticoagulant Therapy

BioPacific Diagnostic Inc supplies anticoagulant therapy products from BioMedica Diagnostic including ACTICHOROME and IMUCLONE assays.

The role of anticoagulant therapies is to block the activity of coagulation factors. Anticoagulant agents may block specific targets in the coagulation cascade. Approved anticoagulants for clinical use in the acute setting of acute coronary syndrome (ACS)/percutaneous coronary interventions (PCI) patients are classified according to their mechanism of action. Thrombin inhibitors are the most commonly used and are classified as indirect and direct thrombin inhibitors. Anti-X inhibitors are also available, although their use is limited in patients undergoing PCI. Blockade of coagulation factors is pivotal as they are associated with enhanced platelet reactivity, thus increasing thrombotic risk.

Antiphospholipid Syndrome

BioPacific Diagnostic Inc supplies Antiphospholipid Syndrome testing products from BioMedica Diagnostic.

Antiphospholipid Syndrome (APS) is an autoimmune, hypercoagulable state caused by antiphospholipid antibodies interfering with the clot formation. APS leads to both arterial and venous thromboses as well as pregnancy related complications such as miscarriage, stillbirth, preterm delivery and severe preeclampsia. The diagnostic criteria for APS consist of one clinical event (i.e. thrombosis or pregnancy complication) and two antibody blood tests spaced at least three months apart that confirm the presence of either lupus anticoagulants or anti-β2-glycoprotein-I antibodies. As β2-glycoprotein-I antibodies are a subset of anti-cardiolipin antibodies, an anti-cardiolipin assay can be performed as a less specific substitute.

Bleeding Profiles

BioPacific Diagnostic Inc carries the complete line of BioMedica’s bleeding profile and screening tests.

Bleeding profiles are screening tests (Activated Partial Thromboplastin Time, Prothrombin Time, Thrombin Time, Fibrinogen, D-dimer) designed to detect abnormal blood clotting. Based on the pathways of the coagulation cascade, the test results when interpreted together are used to identify deficiencies and defects in coagulation factors, the presence of inhibitors to coagulation factors, the effectiveness of blood-thinning medications, hereditary conditions, severe infections and liver problems. The bleeding profile may also be performed to confirm normal blood clotting prior to a surgical procedure.

Cancer Prognosis

FEMTELLE® is intended for the quantitative measurement of human Urokinase-type Plasminogen Activator (uPA) and human Plasminogen Activator Inhibitor Type-1 (PAI-1) in detergent extracts of breast tumor tissue. uPA and PAI-1 are clinically validated independent prognostic markers in breast cancer and have reached the highest Level of Evidence (LoE-1) according to the “Tumor Marker Utility System”.

Chromogenic & Fluorogenic Substrates

A Fluorogenic substrate is a nonfluorescent material that is acted upon by an enzyme to produce a fluorescent compound. Chromogenic substrates are peptides that react with proteolytic enzymes under the formation of color.

Calibrators and Controls

Haematology Controls, Calibrators, and Reagents

D-Dimer

D-dimer is a cross-linked fibrin degradation product (XL-FDP), a small protein fragment present in blood after a clot is degraded during fibrinolysis. Measuring the level of D-dimer in a patient is useful to indicate the presence of a blood clot. Therefore, levels below pre-determined cut-off thresholds may be used to rule out conditions such as Deep Vein Thrombosis (DVT), Pulmonary embolism (PE) and Stroke. A D-dimer level may be used to help diagnose Disseminated Intravascular Coagulation (DIC) and to monitor the effectiveness of DIC treatment.

Thrombotic Risk Markers

For individuals with a documented thrombotic event and a family history of thrombosis, testing coagulation factors is crucial for diagnosing the condition. Deficiencies of natural anticoagulants Antithrombin III, Protein C, Protein S, and factor mutations such as Activated Protein C Resistance may lead to venous thrombosis: Superficial Venous thrombosis (SVT), Deep Venous Thrombosis (DVT) and Pulmonary Embolism (PE). Specific coagulation factors released from the vascular endothelium, Thrombomodulin and Tissue Factor Pathway Inhibitor offer information about endothelial dysfuncti on. When hemostasis is disrupted because thrombi are not degraded, levels of Plasminogen and Plasminogen Activator Inhibitor Type 1 (PAI-1) may provide information to the state of the patient. The mechanisms of thrombosis in cancer patients involve a complex interacti on between the tumor cell, the patient, and the hemostatic system. Tumors may activate coagulation by their expression of Tissue Factor.

Thrombotic Thrombocytopenia Purpura

Thrombotic Thrombocytopenia Purpura (TTP) is a severe, occlusive, microvascular “thrombotic microangiopathy” characterized by low platelet count, microvascular thrombi, red cell fragmentation, central nervous system disorders and renal complications. ADAMTS13, also known as von Willebrand Factor (vWF) cleaving protease, is a zinc metalloproteinase that cleaves ultra large (UL) vWF multimers within the A2 region of vWF. The UL-vWF multimers bind to receptors on platelets inducing platelet aggregation and formation of intravascular microthrombi. Studies have shown that low levels of ADAMTS13 activity are strongly associated with a diagnosis of TTP. Assessing the ADAMTS13 protein levels and the presence of ADAMTS13 autoantibodies presents a comprehensive overview of the patient, identifying the patient’s condition as congenital versus acquired TTP.

Von Willebrand Disease

Von Willebrand disease (VWD), one of the most common inherited bleeding disorders, is characterized by excessive mucosal bleeding and abnormally low levels of high molecular weight von Willebrand Factor (VWF) activity. Following an evaluation of the personal and family history, comprehensive laboratory testing is required to identify specific defects and correctly type VWD patients as recommended by the International Society of Thrombosis and Haemostasis. Guided by results of initial haemostasis testing: CBC with Platelet Count, Activated Partial Thromboplastin Time (APTT), and Prothrombin Time (PT), further laboratory testing on VWF status may confirm the presence of the disorder.